VNDA
Vanda Pharmaceuticals Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow +2.4% ·
net new positions -10.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | 0 | 37.76M | $231.07M | +7 | −7 |
| Q1 2026 | 78 | +6 | 33.85M | $233.91M | +14 | −8 |
| Q4 2025 | 72 | -1 | 30.64M | $270.14M | +1 | −2 |
| Q3 2025 | 17 | 0 | 25.97M | $129.59M | — | −1 |
| Q2 2025 | 15 | 0 | 24.58M | $116.00M | — | — |
| Q1 2025 | 12 | 0 | 9.69M | $44.48M | — | — |
| Q4 2024 | 12 | +1 | 8.66M | $41.48M | +1 | — |
| Q3 2024 | 10 | -1 | 7.15M | $33.54M | — | −1 |
| Q2 2024 | 11 | — | 6.99M | $39.47M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 4.01M | -2.5% | $18.81M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.43M | +7.1% | $6.69M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.43M | +7.1% | $6.69M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 559.80K | -19.2% | $2.63M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 559.80K | -19.2% | $2.63M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 399.51K | +2360.5% | $1.87M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 309.65K | -15.3% | $1.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 309.65K | -15.3% | $1.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 142.44K | -3.4% | $668,020 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 115.00K | 0.0% | $539,350 | 0.0% | Held | 2 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 102.44K | +19.4% | $480,458 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 65.92K | -13.1% | $309,179 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 65.92K | -13.1% | $309,179 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 65.92K | -13.1% | $309,179 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 18.89K | +10.9% | $89,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $138,448 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 168 holders, 45.91M shares, $293.46M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.